287714-35-6

Basic information

• Product Name: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE
• Synonyms: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE;Methyl 2-chloropyriMidine...;2-Chloropyrimidine-5-carboxylic acid methyl ester;2-Chloro-5-(methoxycarbonyl)pyrimidine, 2-Chloro-5-(methoxycarbonyl)-1,3-diazine;2-chloro-pyrimidine-5-carboxylic acid methyl este;EOS-60344
• CAS NO: 287714-35-6
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.5691
• Product Categories: Heterocycles;Heterocycle-Pyrimidine series
• Mol File: 287714-35-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 76 °C
• Boiling Point: 304.3℃
• Flash Point: 138℃
• Appearance: White to off-white powder
• Density: 1.372
• Vapor Pressure: 0.000883mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.14±0.22(Predicted)
• CAS DataBase Reference: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(287714-35-6)
• EPA Substance Registry System: METHYL 2-CHLOROPYRIMIDINE-5-CARBOXYLATE(287714-35-6)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-26-36/37/39
• RIDADR: UN2811
• Hazardous Substances Data: 287714-35-6(Hazardous Substances Data)

Usage

Description

Methyl 2-chloropyrimidine-5-carboxylate is an organic compound with the chemical formula C6H5ClN2O2. It is a white to off-white powder and is known for its potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloropyrimidine-5-carboxylate is used as a key intermediate in the synthesis of ACSS2 inhibitors. These inhibitors exhibit anti-inflammatory and anti-depressant activity, making them valuable for the development of new therapeutic agents to treat various inflammatory and mood disorders.

InChI:InChI=1/C6H5ClN2O2/c1-11-5(10)4-2-8-6(7)9-3-4/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 374068-01-6 2-bromopyrimidine-5-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 308348-93-8 2-amino-pyrimidine-5-carboxylic acid methyl ester 

Downstream Products

• 38373-46-5 methyl 2-methoxy-5-pyrimidinecarboxylate 
• 1035270-11-1 2-(4-cyclopropylpiperazin-1-yl)-N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]pyrimidine-5-carboxamide 
• 1035271-70-5 methyl 2-(4-methyl-1,4-diazepan-1-yl)pyrimidine-5-carboxylate 
• 1246381-01-0 2-{3-chloro-4-[2-(2-chloro-pyridin-4-yl)-3,3,3-trifluoro-2-hydroxy-1-methyl-propyl]-phenoxy}-pyrimidine-5-carboxylic acid methyl ester 
• 1268383-98-7 methyl [2-(2,3-difluorophenyl)-5H-imidazo[4,5-d]pyridazin-5-yl]{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-55-2 2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinecarboxylic acid 
• 1268385-57-4 methyl {2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-58-5 methyl bromo{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}acetate 
• 1268385-56-3 α-diazo-1-{2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinyl}ethanone 
• 1268385-61-0 C₁₅H₁₂ClF₃N₂O₂ 
• 1204529-59-8 methyl 2-[4-(propyloxy)-2-(trifluoromethyl)phenyl]-5-pyrimidinecarboxylate 
• 176240-74-7 methyl 2-isopropylpyrimidine-5-carboxylate 
• 937796-11-7 (2-(pyrrolidin-1-yl)pyrimidin-5-yl)methanol 

Relevant articles and documents

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

CONDENSED BICYCLIC HETEROCYCLIC DERIVATIVE

PROBLEM TO BE SOLVED: To provide a compound having excellent retinoic acid receptor related orphan receptor γt inhibition effect and useful as a therapeutic agent for psoriasis or the like. SOLUTION: There is provided a compound represented by the general

HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The com-pounds can be used in methods of treating proliferative dis-eases and disorders such as cancer